Etid klinik pou Kansè ovè nan Kentucky
25 etid pou Kansè ovè ap chèche patisipan nan sit nan Kentucky.
Vil nan Kentucky
Tèks ofisyèl etid la (Anglè)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- CommonSpirit Saint Joseph Medical Center - East Lexington, Lexington
- University of Kentucky/Markey Cancer Center, Lexington
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT05564377A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0251 - Norton Cancer Institute, Louisville
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05128825A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Baptist Health Lexington /ID# 275218, Lexington
- Norton Cancer Institute - St. Matthews /ID# 276173, Louisville
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Baptist Health Lexington /ID# 278267, Lexington
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Baptist Health Lexington, Lexington
- Norton Women's and Children's Hospital, Louisville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213804Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Norton Cancer Institute, Louisville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Norton Cancer Institute, Louisville
Ap rekriteFaz 2
Laj 18 a 99 · Fanm · Mizajou Sep 15, 2026 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- St Elizabeth Healthcare, Edgewood
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Norton Cancer Institute Research, Louisville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06303505Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Norton Cancer Institute, St. Matthews Clinic, Louisville
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 14, 2026 · NCT06787612A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- St. Elizabeth Healthcare, Edgewood
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06774963Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- University of Kentucky/Markey Cancer Center, Lexington
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07001748A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Baptist Health Corbin, Corbin
- Baptist Health Lexington, Lexington
- Norton Hospital Pavilion and Medical Campus, Louisville
- ak 5 plis
Ap rekrite
Laj 35 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Baptist Health Corbin, Corbin
- Commonwealth Cancer Center-Corbin, Corbin
- ak 10 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- St. Elizabeth Medical Center, Edgewood
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06161025Lead-212 PSV359 Therapy for Patients With Solid Tumors
- University of Kentucky, Lexington
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou Jul 6, 2026 · NCT06710756EXoPERT EMERALD Clinical Study
- Lexington VA Healthcare System, Lexington
- KCTL, Louisville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 45 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT07186296A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
- St. Elizabeth Medical Center - Edgewood /ID# 272113, Edgewood
- Baptist Health Lexington /ID# 272211, Lexington
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou May 26, 2026 · NCT06682988Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- University of Kentucky Medical Center, Lexington
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Apr 16, 2026 · NCT05659381Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
- University of Kentucky, Lexington
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT04779554Combination Therapy for Recurrent Ovarian Cancer
- UofL Health Brown Cancer Center, Louisville
Ap rekriteFaz 1/2
Laj 18 ak plis · Fanm · Mizajou Mar 19, 2026 · NCT05610735A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- University of Kentucky Markey Cancer Center, Lexington
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT06778863First in Human Study of TORL-1-23 in Participants With Advanced Cancer
- University of Kentucky Medical Center, Lexington
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05103683cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Corbin, Corbin
- Baptist Hardin, Elizabethtown
- Baptist Lexington, Lexington
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
- Markey Cancer Center, Lexington
Ap rekriteVolontè an sante akeyi
Laj 24 ak plis · Fanm · Mizajou Nov 14, 2025 · NCT04473833Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.